Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Influenza Clinical Trial

Official title:

A Phase II, Multicenter, Randomized, Double-Blind, Active Comparator Controlled Study of the Immunogenicity and Safety of VAX2012Q, A Quadrivalent Influenza Vaccine in Healthy Adults 18-64 Years

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02434276
• Other study ID #: VAX2012Q-03
• Status: Active, not recruiting
• Phase: Phase 2
• First received: April 16, 2015
• Last updated: June 25, 2015
• Start date: May 2015
• Est. completion date: June 2016

Study information

• Verified date: June 2015
• Source: VaxInnate Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either one of two dose levels of VAX2012Q or a licensed quadrivalent influenza vaccine. The subjects will be randomized at a 1:1:1 ratio.

Description:

This is a multi-center, randomized, double-blind, active comparator controlled study in which up to 450 healthy adults age 18-64 years will be administered either VAX2012Q or Fluzone. Four hundred fifty (450) subjects will be randomized 1:1:1 ratio of either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine.

Randomization will be stratified for age (18-49 and 50-64 years). Subjects will be stratified by two age groups (18-49 and 50-64) and randomized in a 1:1:1 ratio to either 8 or 12 mcg VAX2012Q dose levels or to Fluzone® Quadrivalent vaccine. 25-35% of the total study population will be recruited into the 50-64 age group.

The primary objective of the study is to evaluate the seroconversion rates at Day 21 for both dose levels of VAX2012Q.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 450
• Est. completion date: June 2016
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Males and females, 18-64 years of age.

• Females must be:

1. Surgically sterilized

2. Post menopausal:

• 12 months of spontaneous amenorrhea or

• 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 milli-International Units (mIU)/ml or

• 6 weeks postsurgical bilateral oophorectomy

3. Those of childbearing potential must have a negative pre-treatment serum pregnancy test followed by a confirmatory urine pregnancy test immediately prior to vaccination and must agree to use a reliable form of contraception for at least 21 days post vaccination including contraceptives, intrauterine device, double-barrier method.

• In good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator.

• Must sign informed consent indicating understanding of the purpose of and procedures required for the study and willingness to participate.

Exclusion Criteria:

• Within 6 months preceding the administration of the study vaccine, receiving any licensed or investigational vaccine.

• Within 30 days preceding the administration of the study vaccine, receiving any investigational drug.

• Excessive chronic alcohol use within the last 5 years.

• History of drug abuse, other than recreational cannabis use, within the last 5 years that could affect the subject's participation in the study.

• Significant psychiatric illness within the last 12 months which would interfere with the study.

• A chronic illness that is not medically stable, receiving a concomitant therapy in which the medication dose has not been stable for at least 3 months prior to immunization or has any other condition that could interfere with the study.

• Clinically significant abnormal liver function tests at screening: alanine transaminase (ALT) or aspartate aminotransferase (AST) >2.5 Upper Limit of Normal (ULN).

• Total bilirubin > 1.5 ULN if ALT or AST > ULN or total bilirubin > 2 ULN with ALT and AST within normal range .

• Creatinine >1.7mg/dL, Hemoglobin < 11g/dL for females; <12.5 g/dL for males, white blood cells (WBC) <2500cell/mm3 or > 15,000cell/mm3, Platelet Count <125,000cell/mm3

• Positive serology for HBSAg, hepatitis C virus (HCV) or HIV

• Have cancer or have received treatment for cancer within three years, excluding in situ cervical carcinoma or basal /squamous cell carcinoma of the skin at other than the vaccination site.

• Any autoimmune disease.

• Presently receiving or having a recent history of receiving (= six months) any medication or therapeutic modality that affects the immune system or a drug known to be frequently associated with significant major organ toxicity or system corticosteroids (oral or injectable).

• History of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component.

• Allergic to egg or egg products.

• History of Guillain-Barré Syndrome.

• Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination

• Donation of blood or blood products within 4 weeks prior to vaccination or during the 4 week study period following vaccination.

• Acute disease within 72 hours prior to vaccination.

• An oral temperature >100.4°F (38°C) on the day of vaccination

• Body Mass Index >40.

• Known bleeding disorders or receiving prescribed oral or parenteral anticoagulants.

• Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study or could interfere with study evaluations.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• VAX2012Q
Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
• Fluzone Quadrivalent
Fluzone Quadrivalent (Influenza Vaccine)

Locations

Country	Name	City	State
United States	Optimal Research	Huntsville	Alabama
United States	Optimal Research	Melbourne	Florida
United States	Optimal Research	Mishawaka	Indiana
United States	Optimal Research	Peoria	Illinois
United States	Optimal Research	Rockville	Maryland
United States	Optimal Research	San Diego	California

Sponsors (3)

Lead Sponsor	Collaborator
VaxInnate Corporation	Accelovance, Department of Health and Human Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Duration of immunity	Immune responses will be measured in sera by HAI assay.	Through day 90	No
Other	Breadth of immunity	Immune responses to influenza virus strains not contained in the vaccines will be measured in sera by HAI assay.	Through day 90	No
Primary	Seroconversion rates to the 4 components of VAX2012Q	Immune response to the vaccine will be measured in sera by the hemagglutination inhibition (HAI) assay.	Through day 21	No
Secondary	Safety following vaccination assessed by Adverse events (AEs)	vital signs, laboratory test results and analgesic and antipyretic use to treat symptoms emerging post vaccination will be collected.	Through day 21	Yes
Secondary	Immunogenicity of the two dose levels of VAX2012Q and of Fluzone Quadrivalent	Immune responses to the vaccines will be measured in sera by HAI assay.	Through day 21	No
Secondary	C-reactive protein levels	Measure C-reactive protein levels.	Through day 7	No
Secondary	Long term safety following vaccination assessed by Clinically significant AEs	including Serious Adverse Events, Adverse Events of Special Interest and new onset chronic diseases, will be collected.	After Day 21 through one year	Yes